drugset / Trial / NCT02839889

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

NCT02839889

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of a two week randomized double blind period followed by a two week open-label period.

Timeline

Start
2016-09
Primary completion
2018-01-11
Completion
2018-01-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxegol Small molecule 25 mg